Sponsored content
sponsored content
Get The Policy Briefings Newsletter
Get into the weeds on hot policy issues and the players shaping them.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
FOLLOW THE HILL TIMES:
Want to make sure your whole office has the full Hill Times experience?
We have team plans available for companies, organizations, classes, Parliament Hill offices and more. Fill out this form and find out if your team is eligible for a discount.
More Opinion
Related Stories
- The language in the pharmacare bill is ‘fatally flawed,’ according to pharmacare expert Dr. Steve Morgan.
- The language in the pharmacare bill is ‘fatally flawed,’ according to pharmacare expert Dr. Steve Morgan.
- An expanded pharmacare framework offers a lifeline for millions of people in Canada. It is time for federal, provincial, and territorial governments to deliver it.
- An expanded pharmacare framework offers a lifeline for millions of people in Canada. It is time for federal, provincial, and territorial governments to deliver it.
- If the proposals survive, this national pharmacare intro-package should fill open gaps for many insulin-dependent diabetics, especially those with Type 1 diabetes. But there is scant hope of a full-fledged pharmacare program anytime soon.
- If the proposals survive, this national pharmacare intro-package should fill open gaps for many insulin-dependent diabetics, especially those with Type 1 diabetes. But there is scant hope of a full-fledged pharmacare program anytime soon.
- Displacing comprehensive employer-sponsored drug plans with a single-payer universal pharmacare model would have adverse consequences, including reduced coverage, lost tax revenue, slower access to new drugs, and higher costs for employers, unions, and families.
- Displacing comprehensive employer-sponsored drug plans with a single-payer universal pharmacare model would have adverse consequences, including reduced coverage, lost tax revenue, slower access to new drugs, and higher costs for employers, unions, and families.
- Politics
- Foreign Policy
- Lobbying
- Legislation
- Policy Briefings
- Politics This Morning
- Hill Climbers
- Civil Circles
- Heard On The Hill
- Election
- Finance and Budget
- Public Service
- Exclusive Lists
- Parliamentary Calendar
- Top 100 Lists and Exclusive Features
- Podcasts
- This Week's Paper
- Search
- Archives
- Digital Newspaper Archives
- Politics
- Foreign Policy
- Lobbying
- Legislation
- Policy Briefings
- Politics This Morning
- Hill Climbers
- Civil Circles
- Heard On The Hill
- Election
- Finance and Budget
- Public Service
- Exclusive Lists
- Parliamentary Calendar
- Top 100 Lists and Exclusive Features
- Podcasts
- This Week's Paper
- Search
- Archives
- Digital Newspaper Archives
-
Get free news updates